1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Gwo Xi Stem Cell Applied Technology Co., Ltd.

Gwo Xi Stem Cell Applied Technology Co., Ltd.

TTPEX:6704
22.15
TWD
-0.95
(-4.11%)
2.05BMarket Cap
Gwo Xi Stem Cell Applied Technology Co., Ltd.
TPEX:6704
(Taipei Exchange)

Recent

price

22.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
1.96
2.32
2.15
2.93
2.12
1.58
1.77
1.95
- -
Revenue per Share
-1.72
-1.01
-0.96
-1.27
-1.31
-0.98
-0.87
-0.84
- -
Basic EPS, GAAP
-3.85
-4.04
-2.1
-0.87
-0.96
-0.2
-0.78
-0.84
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.28
6.23
6.72
5.49
5.8
7.76
6.89
6.05
7.78
Book Value per Share
4.25
4.25
4.77
3.59
3.95
6.06
5.21
4.38
6.12
Tangible Book Value per Share
66
76
88
83
85
90
96
96
96
Basic Weighted Avg Shares
128
177
189
243
181
141
170
187
- -
Sales/Revenue/Turnover
-88.37
-48.49
-38.23
-41.78
-63.59
-66.7
-44.66
-39.39
- -
Operating Margin (%)
18
29
26
35
59
58
58
58
- -
Depreciation Expense
-113
-77
-84
-106
-112
-88
-83
-81
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-87.95
-43.54
-44.66
-43.48
-62.05
-62.4
-49
-43.05
- -
Profit Margin (%)
261
181
168
43
94
309
231
113
286
Working Capital
207
379
467
458
428
366
322
283
269
LT Debt
588
593
598
492
510
744
661
580
747
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-13.99
-14.79
-19.67
-22.59
-14.04
-11.86
-12.97
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
42
82
87
LT Borrowings
264
243
226
LT Finance Leases
41
40
43
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
96
96
Market Capitalization
2,365
2,591
2,049

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
256
227
387
Cash, Cash Equivalents & STI
212
203
362
Accounts Receivable, Net
33
13
16
Inventories
11
11
8
Total Current Liabilities
83
115
102
Payables & Accruals
- -
- -
- -
ST Debt
42
82
87
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.69%
-12.18%
Free Cash Flow
- -
40.94%
7.2%
Net Income, GAAP
- -
0.27%
-3.36%
Sales/Revenue/Turnover
- -
2.35%
10%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
170
2025
- -
- -
187
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.87
2025
- -
- -
-0.84
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) is a clinical-stage biopharmaceutical company focused on developing stem cell therapies and exosome-based products to address unmet medical needs in regenerative medicine. Founded in 2011 and headquartered in Hsinchu Biomedical Science Park, Taiwan, the company offers a pharmaceutical-grade stem cell production platform, Nigiro-Med stem cell activation technology, clinical-grade cell storage services, cell preparation quality testing, and CDMO/CMO services for stem cells and exosomes; its pipeline includes four investigational stem cell medicines--GXCPC1 for knee osteoarthritis (Phase III trial approved), GXNPC1 for chronic stroke (Phase II completed, pursuing conditional approval), GXIPC1 for diabetes (Phase I completed in Vietnam), and a therapy for liver cirrhosis--along with mesenchymal stem cell-derived exosomes granted an INCI name for cosmetic applications. The company operates primarily in Taiwan with international clinical collaborations in Vietnam and partnerships in Malaysia and Japan, targeting patients with conditions such as osteoarthritis, stroke, diabetes, liver cirrhosis, and wound healing, while expanding into anti-aging cosmetics and global supply chain services through its PIC/S GMP facility. Recent developments include Phase III approval for GXCPC1 in 2025, a Memorandum of Understanding with Malaysia's Cell 101 International Sdn Bhd for Asia-Pacific expansion, a Taiwan invention patent for wound repair compositions, INCI certification and U.S. FDA Drug Master File submission for exosomes, GXIPC1 Phase I results approval in Vietnam, and pursuit of PIC/S GMP certification by end-2025 to support commercialization and out-licensing.